Moderna Stock Is Surging: What's Going On?
Key takeaways
- Moderna’s melanoma trial success fuels a sharp rally, but analyst consensus remains cautious.
- MRNA shares up 8.18% to $157.53
- Average analyst target $91
- Rothschild target $81
What happened
Moderna Inc. (NASDAQ: MRNA) shares jumped 8.18% to $157.53 on Thursday after the company announced a Phase 3 melanoma trial that showed its personalized cancer vaccine, intismeran autogene, combined with Merck’s Keytruda, outperformed Keytruda alone in high‑risk melanoma patients.
Why it matters
The trial is the first Phase 3 success for a personalized neoantigen vaccine and for any mRNA‑based cancer therapy, signaling a breakthrough in oncology and potentially opening a new revenue stream for Moderna beyond COVID‑19 vaccines.
Short-term and longer-term
Short-term. Short‑term traders should watch MRNA’s price action around the $157 level, as the recent 8% jump may create a new support zone.
Longer-term. Longer‑term investors should assess how the melanoma success fits into Moderna’s overall oncology strategy, including the nine‑trial program across melanoma, lung, bladder, and kidney cancers.